Kunwoo Lee

Kunwoo Lee

Auto-generated profile, based on publicly available information

Kunwoo Lee

University of California

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2017 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
KLKunwoo Lee
Kunwoo Lee
MCMichael Conboy
Michael Conboy
HPHyo Min Park
Hyo Min Park
FJFuguo Jiang
Fuguo Jiang
HKHyun Jin Kim
Hyun Jin Kim
Niren MurthyNiren Murthy
Niren Murthy
Clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR associated protein 9 (Cas9)-based therapeutics, especially those that can correct gene mutations via homology-directed repair, have the potential to revolutionize the treatment of genetic diseases. However, it is challenging to develop homology-directed repair-based therapeutics because they require the simultaneous in vivo delivery of Cas9 protein, guide RNA and donor DNA. Here, we demonstrate that a delivery vehicle composed of gold nanoparticles conjugated to DNA and complexed with cationic endosomal disruptive polymers can deliver Cas9 ribonucleoprotein and donor DNA into a wide variety of cell types and efficiently correct the DNA mutation that causes Duchenne muscular dystrophy in mice via local injection, with minimal off-target DNA damage.

2 May 2017 in eLife
Verified
Journal Article
Open access
KLKunwoo Lee
Kunwoo Lee
VMVanessa A Mackley
Vanessa A Mackley
ARAnirudh Rao
Anirudh Rao
ACAnthony T Chong
Anthony T Chong
MDMark A Dewitt
Mark A Dewitt
Niren MurthyNiren Murthy
Niren Murthy
Chemical modification of the gRNA and donor DNA has great potential for improving the gene editing efficiency of Cas9 and Cpf1, but has not been investigated extensively. In this report, we demonstrate that the gRNAs of Cas9 and Cpf1, and donor DNA can be chemically modified at their terminal positions without losing activity. Moreover, we show that 5’ fluorescently labeled donor DNA can be used as a marker to enrich HDR edited cells by a factor of two through cell sorting. In addition, we demonstrate that the gRNA and donor DNA can be directly conjugated together into one molecule, and show that this gRNA-donor DNA conjugate is three times better at transfecting cells and inducing HDR, with cationic polymers, than unconjugated gRNA and donor DNA. The tolerance of the gRNA and donor DNA to chemical modifications has the potential to enable new strategies for genome engineering.

17 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
HPHyo Min Park
Hyo Min Park
HLHui Liu
Hui Liu
JWJoann Wu
Joann Wu
ACAnthony Chong
Anthony Chong
VMVanessa Mackley
Vanessa Mackley
KLKunwoo Lee
Kunwoo Lee
Engineering of the Cpf1 crRNA has the potential to enhance its gene editing efficiency and non-viral delivery to cells. Here, we demonstrate that extending the length of its crRNA at the 5′ end can enhance the gene editing efficiency of Cpf1 both in cells and in vivo. Extending the 5′ end of the crRNA enhances the gene editing efficiency of the Cpf1 RNP to induce non-homologous end-joining and homology-directed repair using electroporation in cells. Additionally, chemical modifications on the extended 5′ end of the crRNA result in enhanced serum stability. Also, extending the 5′ end of the crRNA by 59 nucleotides increases the delivery efficiency of Cpf1 RNP in cells and in vivo cationic delivery vehicles including polymer nanoparticle. Thus, 5′ extension and chemical modification of the Cpf1 crRNA is an effective method for enhancing the gene editing efficiency of Cpf1 and its delivery in vivo.

8 March 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
Kiana AranKiana Aran
Kiana Aran
MCMarc Chooljian
Marc Chooljian
JPJacobo Paredes
Jacobo Paredes
MRMohammad Rafi
Mohammad Rafi
KLKunwoo Lee
Kunwoo Lee
DLDorian Liepmann
Dorian Liepmann
A needle-free device delivers a liquid jet of vaccine that penetrates the buccal mucosa and elicits antibody production in rabbits.

27 July 2023 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
JPJuliana Popovitz
Juliana Popovitz
RSRohit Sharma
Rohit Sharma
RHReyhane Hoshyar
Reyhane Hoshyar
BKBeob Soo Kim
Beob Soo Kim
Niren MurthyNiren Murthy
Niren Murthy
KLKunwoo Lee
Kunwoo Lee

27 April 2015 in Nature Materials
Verified
Journal Article
Open access
PDF file
KLKunwoo Lee
Kunwoo Lee
MRMohammad Rafi
Mohammad Rafi
XWXiaojian X. Wang
Xiaojian X. Wang
KAKiana Aran
Kiana Aran
XFXuli Feng
Xuli Feng
Niren MurthyNiren Murthy
Niren Murthy
Clinical translation of transcription factor therapeutics is limited by delivery problems. Now, an oligonucleotide that can bind and deliver transcription factors with high in vivo efficiency and treat acetaminophen-induced liver injury is reported. Therapeutics based on transcription factors have the potential to revolutionize medicine but have had limited clinical success as a consequence of delivery problems1,2,3,4. The delivery of transcription factors is challenging because it requires the development of a delivery vehicle that can complex transcription factors, target cells and stimulate endosomal disruption, with minimal toxicity5,6. Here, we present a multifunctional oligonucleotide, termed DARTs (DNA assembled recombinant transcription factors), which can deliver transcription factors with high efficiency in vivo. DARTs are composed of an oligonucleotide that contains a transcription-factor-binding sequence and hydrophobic membrane-disruptive chains that are masked by acid-cleavable galactose residues. DARTs have a unique molecular architecture, which allows them to bind transcription factors, trigger endocytosis in hepatocytes, and stimulate endosomal disruption. The DARTs have enhanced uptake in hepatocytes as a result of their galactose residues and can disrupt endosomes efficiently with minimal toxicity, because unmasking of their hydrophobic domains selectively occurs in the acidic environment of the endosome. We show that DARTs can deliver the transcription factor nuclear erythroid 2-related factor 2 (Nrf2) to the liver, catalyse the transcription of Nrf2 downstream genes, and rescue mice from acetaminophen-induced liver injury.